European Cancer Organisation

Focus on breast cancer at ECCO2017

Focus on breast cancer at ECCO2017

As a multidisciplinary congress centred on the very latest clinically-oriented data, ECCO2017 is the ideal platform to provide you with a comprehensive, multidisciplinary assessment of new findings in breast cancer. In addition, breast cancer specialists will gain practical insights impacting their clinical practice.

Key highlights at ECCO2017 will be the Multidisciplinary Tumour Boards, which discuss case presentations examining important issues and during which the audience has the opportunity to participate. For the breast cancer-specific Multidisciplinary Tumour Boards, the cases will explore the management of the axilla (moderated by Isabel T. Rubio on 28 January) and the limitations of breast conservation (moderated by Emiel J.T. Rutgers on 30 January) and are anticipated to prompt lively debates.

A Proffered Paper session on 29 January is expected to be a source of exciting new data in the breast cancer field.

A Clinical Symposium on 28 January will scrutinise the latest trials in breast cancer, which will be presented by the principal investigators. The trials were selected because their findings have been proposed to change clinical practice. Among the trials are: MINDACT, a prospective, randomised study comparing the 70-gene expression signature with common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in node-negative breast cancer will be presented by Martine Piccart.   The data of this study was presented at the AACR annual meeting in 2016.  In 2014, UNICANCER (composed of 18 French Comprehensive Cancer Centers) launched the Epidemiological Strategy and Medical Economics (ESME) program to centralize real-world data in oncology. Metastatic breast cancer (mBC) was first selected to address the value of bevacizumab (B) added to paclitaxel (P) as first-line chemotherapy (CT) for HER2-negative tumours, results of which were presented at ASCO 2016; at the ECCO2017 Suzette Delaloge will present outcome data for HER2 positive patients. GEC-ESTRO, a 5 year follow up of a phase 3, randomised, non-inferiority trial, accelerated partial breast irradiation (APBI) for patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment was compared with whole-breast irradiation will be presented by Vratislav Strnad. The data of this study was published in the Lancet in January 201.  ; Charlotte E. Coles will present  the IMPORT LOW trial which examined the local recurrence data of women with early breast cancer who received partial breast radiotherapy, the first results were presented at the 10th European Breast Cancer Conference in 2016. These trials will be discussed in the critical review session to assess whether they will change practice.

A new format unique to ECCO2017 is the Critical Review session. Trials that have been presented in the clinical symposium and proffered paper sessions will be critical reviewed from a multidisciplinary perspective and their anticipated impact on clinical practice will be explored on 29 January. Chaired by Olivia Pagani, this much-anticipated session will involve a medical oncologist, a radiation oncologist and -a surgical oncologist. The presentations from the multidisciplinary experts will be followed by a roundtable discussion with a panel including the speakers,  a nurse, and  a patient advocate representative and the audience. Consensus by voting will be reached on which developments are truly practice changing.

If you are a breast cancer specialist and you want a definitive, multidisciplinary and practical review of all the new developments, join us at ECCO2017 and find out what you can do today for your patients. Take a look at what’s on offer in the ECCO2017 programme.

Young Trialist Grant

Are you a young clinical oncologist eager to design your own clinical trial?  Then our Young Trialist Grant is for you!  Apply for a unique opportunity to present your ideas to key opinion leaders at ECCO2017.

Deadline: 1 September 2016

Page last modified: